Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma

Figure 4

Ribociclib significantly enhances the in vivo efficacy of chemotherapy and immunotherapy in a sensitive but not resistant xenograft RCC model. Combination of ribociclib with 5-FU or IFN-α is significantly more effective in inhibiting 786-O (a) but not CaKi-1 (b) tumor growth than 5-FU or IFN-α alone. The RCC xenograft mouse model was established using 786-O or Caki-1 cells. , compared to 5-FU or IFN-α alone.

(a)

(b)